Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Woosley

Showing results (31-40 of 201) with videos related to

Pageof 21
Sort By:
BMJ (Clinical Research Ed.)|March 17, 2001
Registry for torsades de pointes with drug treatment existsM J Kilborn, R L Woosley
Clinical Pharmacology and Therapeutics|July 1, 1996
Survey of clinical pharmacology training in the United States and CanadaL R Cantilena, R L Woosley
The New England Journal of Medicine|November 4, 1976
GuanethidineR L Woosley, A S Nies
The New England Journal of Medicine|May 12, 1994
Evaluating drugs after their approval for clinical useR L Woosley, D A Flockhart
American Heart Journal|February 1, 1985
QT prolongation and arrhythmia suppressionD M Roden, R L Woosley
The New England Journal of Medicine|June 11, 1992
Familial dilated cardiomyopathyS S Coughlin, R L Woosley
The American Journal of Cardiology|May 22, 1978
Pharmacokinetics of antiarrhythmic drugsR L Woosley, D G Shand
Clinical Pharmacology and Therapeutics|December 1, 1992
The clinical value of FDA class C drugs approved from 1981 to 1988S U Yasuda, R L Woosley
The American Journal of Cardiology|April 30, 1987
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugsR L Woosley, D M Roden
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|September 1, 1973
Influence of theobromine magnesium oleate on formation of experimental atheromaR L Woosley, D H Will
Pageof 21

Showing results (31-40 of 201) with videos related to

Sort By:
Pageof 21
BMJ (Clinical Research Ed.)|March 17, 2001
Registry for torsades de pointes with drug treatment existsM J Kilborn, R L Woosley
Clinical Pharmacology and Therapeutics|July 1, 1996
Survey of clinical pharmacology training in the United States and CanadaL R Cantilena, R L Woosley
The New England Journal of Medicine|November 4, 1976
GuanethidineR L Woosley, A S Nies
The New England Journal of Medicine|May 12, 1994
Evaluating drugs after their approval for clinical useR L Woosley, D A Flockhart
American Heart Journal|February 1, 1985
QT prolongation and arrhythmia suppressionD M Roden, R L Woosley
The New England Journal of Medicine|June 11, 1992
Familial dilated cardiomyopathyS S Coughlin, R L Woosley
The American Journal of Cardiology|May 22, 1978
Pharmacokinetics of antiarrhythmic drugsR L Woosley, D G Shand
Clinical Pharmacology and Therapeutics|December 1, 1992
The clinical value of FDA class C drugs approved from 1981 to 1988S U Yasuda, R L Woosley
The American Journal of Cardiology|April 30, 1987
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugsR L Woosley, D M Roden
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|September 1, 1973
Influence of theobromine magnesium oleate on formation of experimental atheromaR L Woosley, D H Will
Pageof 21